MedTrace Logo

SVF (Adipose Tissue Derived MSC) Based Therapy for CKD.

NCT03939741 · Status: UNKNOWN · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 31

Last updated 2023-08-01

No results posted yet for this study

Summary

1. To assess the safety of stromal vascular fraction (Autologous Non-Expanded ADSC) injection in patients with Chronic Kidney Disease (CKD).
2. To assess the efficacy of stromal vascular fraction (Autologous Non-Expanded ADSC) injection in patients with Chronic Kidney Disease (CKD).

Conditions

  • Chronic Kidney Diseases

Interventions

BIOLOGICAL

SVF Containg Autologous Non Expanded ADSC

5 ml of SVF containing Autologous Non Expanded ADSC will be injected intravenously and outcome will be observed over the period of 1(one) year.

Sponsors & Collaborators

  • Bangladesh Laser & Cell Surgery Institute & Hospital

    lead OTHER

Principal Investigators

  • Prof. Dr. Md. Firoj Khan, MBBS,FRCP,MD · Bangladesh Laser and Cell Surgery Institute and Hospital, Dhaka, Bangladesh.

  • Dr. Mohammed Yakub Ali MBBS, MPhil, MSc, PhD · Bangladesh Laser and Cell Surgery Institute and Hospital, Dhaka, Bangladesh.

  • Dr. Jahangir Md. Sarwar, MBBS, FCPS · Bangladesh Laser and Cell Surgery Institute and Hospital, Dhaka, Bangladesh.

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-04-01
Primary Completion
2024-03-31
Completion
2025-03-31

Countries

  • Bangladesh

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03939741 on ClinicalTrials.gov